FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Commentary|Podcasts|June 25, 2024 (Updated: June 25, 2024)
Shining the Spotlight on Queer Joy and Resilience in LGBTQ+ Youth
Author(s)Maggie L. Shaw
In our fourth Pride Month podcast episode, we are speaking with Domenico Ruggerio, executive director of We Are Family, in Charleston, South Carolina, the state's oldest nonprofit to provide life-affirming and life-saving programs for lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+) youth.
Advertisement
Welcome to another episode of
In our conversation, we hit on the importance of
And please check out our earlier episodes with
Listen above or through one of these podcast services:
Advertisement
Related to this article
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
5